Geode Capital Management, LLC Tcr2 Therapeutics Inc. Transaction History

Geode Capital Management, LLC

  • $1.12 Trillion
  • Q2 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023
SELL
$0.83 - $1.44 $641 - $1,113
-773 Reduced 0.24%
315,377 $314,000
Q3 2022

Nov 14, 2022
BUY
$1.86 - $3.75 $8,715 - $17,572
4,686 Added 1.5%
316,150 $569,000
Q2 2022

Aug 12, 2022
SELL
$2.11 - $2.94 $480,122 - $668,985
-227,546 Reduced 42.22%
311,464 $903,000
Q1 2022

May 13, 2022
SELL
$2.4 - $4.71 $197,860 - $388,301
-82,442 Reduced 13.27%
539,010 $1.49 Million
Q4 2021

Feb 11, 2022
BUY
$4.58 - $8.34 $765,405 - $1.39 Million
167,119 Added 36.78%
621,452 $2.9 Million
Q3 2021

Nov 12, 2021
SELL
$8.44 - $18.35 $316,525 - $688,180
-37,503 Reduced 7.63%
454,333 $3.87 Million
Q2 2021

Aug 13, 2021
BUY
$16.41 - $24.71 $599,391 - $902,557
36,526 Added 8.02%
491,836 $8.07 Million
Q1 2021

May 12, 2021
BUY
$20.38 - $34.07 $1.65 Million - $2.76 Million
80,912 Added 21.61%
455,310 $10.1 Million
Q4 2020

Feb 12, 2021
BUY
$19.0 - $32.63 $516,895 - $887,699
27,205 Added 7.84%
374,398 $11.6 Million
Q3 2020

Nov 13, 2020
BUY
$13.1 - $20.69 $1.35 Million - $2.12 Million
102,685 Added 42.0%
347,193 $7.05 Million
Q2 2020

Aug 13, 2020
BUY
$6.51 - $16.85 $345,056 - $893,117
53,004 Added 27.68%
244,508 $3.76 Million
Q1 2020

May 14, 2020
BUY
$6.01 - $16.01 $94,867 - $252,717
15,785 Added 8.98%
191,504 $1.48 Million
Q4 2019

Feb 13, 2020
BUY
$12.17 - $17.88 $164,879 - $242,238
13,548 Added 8.35%
175,719 $2.51 Million
Q3 2019

Nov 12, 2019
BUY
$10.15 - $19.53 $1.24 Million - $2.38 Million
121,894 Added 302.64%
162,171 $2.44 Million
Q2 2019

Aug 14, 2019
BUY
$13.64 - $20.97 $549,378 - $844,608
40,277 New
40,277 $576,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email